These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11282165)

  • 1. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone.
    Brenner T; Arnon R; Sela M; Abramsky O; Meiner Z; Riven-Kreitman R; Tarcik N; Teitelbaum D
    J Neuroimmunol; 2001 Apr; 115(1-2):152-60. PubMed ID: 11282165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients.
    Qin Y; Zhang DQ; Prat A; Pouly S; Antel J
    J Neuroimmunol; 2000 Aug; 108(1-2):201-6. PubMed ID: 10900354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
    J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients.
    Farina C; Vargas V; Heydari N; Kümpfel T; Meinl E; Hohlfeld R
    J Neuroimmunol; 2002 Feb; 123(1-2):188-92. PubMed ID: 11880163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells.
    Farina C; Then Bergh F; Albrecht H; Meinl E; Yassouridis A; Neuhaus O; Hohlfeld R
    Brain; 2001 Apr; 124(Pt 4):705-19. PubMed ID: 11287371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.
    Basile E; Gibbs E; Aziz T; Oger J
    J Neuroimmunol; 2006 Aug; 177(1-2):161-6. PubMed ID: 16765453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years.
    Chen M; Conway K; Johnson KP; Martin R; Dhib-Jalbut S
    J Neurol Sci; 2002 Sep; 201(1-2):71-7. PubMed ID: 12163197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines.
    Maron R; Slavin AJ; Hoffmann E; Komagata Y; Weiner HL
    Int Immunol; 2002 Feb; 14(2):131-8. PubMed ID: 11809732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.
    Karussis D; Teitelbaum D; Sicsic C; Brenner T;
    J Neuroimmunol; 2010 Mar; 220(1-2):125-30. PubMed ID: 20153903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.
    Teitelbaum D; Brenner T; Abramsky O; Aharoni R; Sela M; Arnon R
    Mult Scler; 2003 Dec; 9(6):592-9. PubMed ID: 14664472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term evolution of autoreactive T cell repertoire in multiple sclerosis.
    Vergelli M; Mazzanti B; Traggiai E; Biagioli T; Ballerini C; Parigi A; Konse A; Pellicanò G; Massacesi L
    J Neurosci Res; 2001 Nov; 66(3):517-24. PubMed ID: 11746371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis.
    Greer JM; Csurhes PA; Cameron KD; McCombe PA; Good MF; Pender MP
    Brain; 1997 Aug; 120 ( Pt 8)():1447-60. PubMed ID: 9278634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.
    Miller A; Shapiro S; Gershtein R; Kinarty A; Rawashdeh H; Honigman S; Lahat N
    J Neuroimmunol; 1998 Dec; 92(1-2):113-21. PubMed ID: 9916886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
    Karandikar NJ; Crawford MP; Yan X; Ratts RB; Brenchley JM; Ambrozak DR; Lovett-Racke AE; Frohman EM; Stastny P; Douek DC; Koup RA; Racke MK
    J Clin Invest; 2002 Mar; 109(5):641-9. PubMed ID: 11877472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms.
    Stern JN; Illés Z; Reddy J; Keskin DB; Sheu E; Fridkis-Hareli M; Nishimura H; Brosnan CF; Santambrogio L; Kuchroo VK; Strominger JL
    Proc Natl Acad Sci U S A; 2004 Aug; 101(32):11743-8. PubMed ID: 15292514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis.
    Deraos G; Rodi M; Kalbacher H; Chatzantoni K; Karagiannis F; Synodinos L; Plotas P; Papalois A; Dimisianos N; Papathanasopoulos P; Gatos D; Tselios T; Apostolopoulos V; Mouzaki A; Matsoukas J
    Eur J Med Chem; 2015 Aug; 101():13-23. PubMed ID: 26112377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone).
    Johnson KP
    Mult Scler; 1996 Jul; 1(6):325-6. PubMed ID: 9345409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.
    Chen M; Gran B; Costello K; Johnson K; Martin R; Dhib-Jalbut S
    Mult Scler; 2001 Aug; 7(4):209-19. PubMed ID: 11548979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
    Ragheb S; Abramczyk S; Lisak D; Lisak R
    Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.